HeartBeam, Inc. — Form 8-K Summary
Business Context and Reporting Period
HeartBeam, Inc. filed a Current Report on Form 8-K dated May 2, 2024, reporting events occurring on May 1 and May 2, 2024. The filing concerns a new equity sales agreement and termination of the company’s prior sales agreement.
Key Financial and Capital Markets Information
- The company may offer and sell up to approximately $17.0 million of common stock from time to time through Public Ventures, LLC under an at-the-market offering.
- Public Ventures will receive a commission equal to 3.0% of gross proceeds from each sale, plus reimbursement of certain expenses.
- Net proceeds are intended for working capital, general corporate purposes, and any other purposes described in a future prospectus supplement.
- The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or operating-performance figures.
Material Changes Versus the Prior Comparable Period
- On May 2, 2024, HeartBeam entered into a new Sales Agreement with Public Ventures pursuant to its existing Form S-3 registration statement.
- On May 1, 2024, the company terminated its prior Sales Agreement with A.G.P./Alliance Global Partners, providing the required five days’ written notice under that agreement.
Guidance, Outlook, Risks, and Unusual Items
- The company is not obligated to issue or sell any shares under the new agreement and provided no assurance that any shares will be sold.
- Any equity sales could dilute existing stockholders and increase the company’s available funding for working capital and general corporate needs.
- Sales may occur through an at-the-market program or, if specified by the company, through another legally permitted method, subject to market conditions, company instructions, applicable law, and Nasdaq rules.
- The company agreed to provide Public Ventures customary indemnification for certain liabilities, including liabilities under federal securities laws.
- The filing provides no operating guidance or forecast.
Investor Verification Points
- Verify the full terms of the Public Ventures Sales Agreement filed as Exhibit 10.1.
- Monitor whether, and at what prices, shares are sold under the approximately $17.0 million facility.
- Assess the impact of the 3.0% sales commission, expense reimbursements, and any resulting equity dilution.
- Review subsequent filings for proceeds raised, remaining capacity, use of proceeds, and updated liquidity information.
- Confirm the effective termination and any remaining obligations under the former A.G.P./Alliance Global Partners agreement.